Clinical Trial Update: Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of teplizumab (MGA031) in recent-onset type 1 diabetes in children and adults was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Teplizumab (Teplizumab)

Snippet

Sponsor: MacroGenics | Conditions: Type 1 Diabetes Mellitus | Phase 3 | Status: TERMINATED | Results posted: 2023-12-20